Search form

Search form

Eli Lilly reports its new cancer drug enzastaurin was able to shrink brain tumors in up to 25% of patients in a trial and stopped tumor growth in another 10%. The drug, which Lilly hopes to get to the market by 2008, cuts off drug supply to tumors and disrupts cell pathway signaling that is vital to tumor cells' survival.

Related Summaries

Denovo Biopharma secured the rights to further develop, manufacture and market enzastaurin, a cancer drug candidate developed by Eli Lilly & Co. Lilly discontinued the drug's development after it failed to hit the main goal of a late-stage trial in patients with diffuse large B-cell lymphoma. Enzastaurin, however, significantly enhanced progression-free survival in a subset of patents, and Denovo plans to do research to identify biomarkers linked to that outcome.

A biomarker found on the surface of drug-resistant breast, lung and pancreatic tumor cells induced tumor metastasis through the development of stem cell-like properties, according to a study published in the journal Nature Cell Biology. Scientists discovered a pathway used by tumor cells to change into cancer stem cells as well as allow tumors to become resistant to standard cancer drugs. This discovery could allow scientists to reverse cancer cells' stem-like features and drug resistance.

Eli Lilly reports its new cancer drug enzastaurin was able to shrink brain tumors in up to 25% of patients in a trial and stopped tumor growth in another 10%. The drug, which Lilly hopes to get to the market by 2008, cuts off drug supply to tumors and disrupts cell pathway signaling that is vital to tumor cells' survival.

Eli Lilly reports its new cancer drug enzastaurin was able to shrink brain tumors in up to 25% of patients in a trial and stopped tumor growth in another 10%. The drug, which Lilly hopes to get to the market by 2008, cuts off drug supply to tumors and disrupts cell pathway signaling that is vital to tumor cells' survival.

Patients receiving chemotherapy to shrink tumors before surgery for hard-to-cure cancers lived longer than patients who received surgery alone, according to a study involving Eli Lilly's Gemzar, and a second with a chemotherapy cocktail of standard cancer drugs. The first study involved patients with pancreatic cancer and the second with gastric cancer, which affects the lower esophagus and stomach.